Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study is a research paper published in Journal of Clinical Oncology (2024). On theSindex it has a DataRank of 1.4. It has been cited 60 times, with 56 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.617
From this paper's citation signal
Citation Network Contribution
0.737
From 31 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 56 citers.
NCI NIH HHS
Grant: R01 CA238236
NCI NIH HHS
Grant: U54 CA224081
NCI NIH HHS
Grant: P30 CA093373
National Institutes of Health
Grant: 3U54CA224081-01S1
Bay Area Team Against Resistance
Fields of Study
MeSH Terms
Keywords